Eflornithine-sulindac combo may not offer extra benefit for familial adenomatous polyposis

Reuters Health - 09/09/2020 - Combining eflornithine and sulindac to treat people with familial adenomatous polyposis appears no more effective at preventing disease progression than the individual drugs alone, according to a new randomized trial. Progression was seen in 32% of 56 volunteers who received the combination for up to four years compared with 38% of 58 who got sulindac alone and 40% of the 57 treated with eflornithine alone. Those differences were not statistically significant, the researchers report in The New England Journal of Medicine. For the comparison of the drug combination against sulindac, the hazard ratio was 0.71, but the 95% confidence interval was 0.39 to 1.32. Against eflornithine, that hazard ratio was 0.66, with a confidence interval of 0.36 to 1.23. A 2018 study published in JAMA Oncology concluded that the combination was better than placebo, decreasing the number of polyps in the duodenum by about 70%. But the new study compare...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 9 September, 202016 September, 2020